How should I acutely manage a patient with wheezing (possible asthma or COPD exacerbation), including bronchodilator dosing, ipratropium use, oral corticosteroid regimen, oxygen targets, and escalation steps if symptoms persist?

Acute Management of Wheezing (Asthma or COPD Exacerbation)

Immediate Bronchodilator Therapy

Administer combined short-acting β₂-agonist (salbutamol 2.5–5 mg) plus short-acting anticholinergic (ipratropium 0.25–0.5 mg) via nebulizer every 4–6 hours during the acute phase, as this combination provides superior bronchodilation lasting 4–6 hours compared with either agent alone. 1

Initial Dosing Protocol

• For severe exacerbations, give three consecutive doses every 20 minutes (one 3 mL DuoNeb vial containing 0.5 mg ipratropium + 2.5 mg albuterol per dose) to achieve rapid bronchodilation 2
• After initial stabilization, continue nebulized therapy every 4–6 hours for 24–48 hours or until clear clinical improvement occurs 1, 2
• In asthma exacerbations, the combination improves FEV₁ by 7.3% and peak flow by 22.1% more than β-agonist alone 3
• Patients with peak flow <140 L/min gain maximum benefit from combined therapy, with peak flow rising 77% versus 31% with salbutamol alone 4

Delivery Method Considerations

• Metered-dose inhalers with spacer are equally effective as nebulizers for most patients and should be preferred when coordination allows 1
• Nebulizers must be powered by compressed air (not oxygen) in patients with suspected hypercapnia, with supplemental oxygen delivered concurrently via nasal cannula at 1–2 L/min 1, 2
• Transition to hand-held inhalers within 24–48 hours once clinical improvement is evident 2

---

Systemic Corticosteroid Regimen

Give oral prednisone 30–40 mg once daily for exactly 5 days starting immediately; this short course is as effective as a 14-day regimen while reducing cumulative steroid exposure by more than 50%. 1

• Oral administration is equally effective to intravenous and should be the default route unless oral intake is impossible 1
• This regimen improves lung function and oxygenation, shortens recovery time, reduces treatment failure by >50%, and lowers 30-day rehospitalization risk 1
• Do not extend systemic corticosteroids beyond 5–7 days unless another indication exists 1

---

Oxygen Therapy Targets

Target oxygen saturation of 88–92% using controlled-delivery devices (Venturi mask 24–28% or nasal cannula 1–2 L/min) to correct life-threatening hypoxemia while minimizing CO₂ retention. 1

Monitoring Protocol

• Obtain arterial blood gas within 60 minutes of initiating oxygen to identify hypercapnia (PaCO₂ >45 mmHg) or acidosis (pH <7.35) 1
• Repeat ABG at 30–60 minutes if the patient deteriorates or if initial pH is <7.35 1
• If initial ABG shows normal pH and PaCO₂, the saturation target may be increased to 94–98% only if the patient has no prior hypercapnic failure requiring NIV and their usual stable saturation is ≥94% 1
• High-flow oxygen (>28% FiO₂ or >4 L/min) without blood-gas monitoring worsens hypercapnic respiratory failure and increases mortality by approximately 78% 1

---

Antibiotic Therapy (When Indicated)

Prescribe antibiotics for 5–7 days when sputum purulence is present together with either increased dyspnea OR increased sputum volume (two of three cardinal symptoms, with purulence required). 1

Antibiotic Selection

• First-line agents: amoxicillin-clavulanate 875/125 mg twice daily, doxycycline 100 mg twice daily, or a macrolide (azithromycin or clarithromycin) 1
• This approach reduces short-term mortality by approximately 77%, treatment failure by 53%, and sputum purulence by 44% 1
• Most common organisms are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis 1

---

Escalation to Non-Invasive Ventilation

Initiate NIV immediately as first-line therapy when acute hypercapnic respiratory failure (PaCO₂ >45 mmHg) with acidosis (pH <7.35) persists for more than 30 minutes after standard medical treatment. 1

NIV Indications and Benefits

• Additional indications: persistent hypoxemia despite oxygen, severe dyspnea with respiratory muscle fatigue, or respiratory rate ≥25–30 breaths/min 1
• NIV improves gas exchange, reduces work of breathing, decreases intubation rates by approximately 50%, shortens hospital stay, and improves survival 1
• Success rates in appropriately selected patients are 80–85% 1
• Transfer to ICU if pH remains <7.26 despite NIV 1

Contraindications to NIV

• Altered mental status with inability to protect airway, large-volume secretions, hemodynamic instability, or recent facial/upper-airway surgery require invasive mechanical ventilation 1

---

Hospitalization Criteria

Admit or evaluate in the emergency department if any of the following are present:

• Marked increase in dyspnea unresponsive to outpatient therapy 1
• Respiratory rate >30 breaths/min 1
• Inability to eat or sleep because of respiratory symptoms 1
• New or worsening hypoxemia (SpO₂ <90% on room air) 1
• New or worsening hypercapnia (PaCO₂ >45 mmHg) 1
• Altered mental status or loss of alertness 1
• Persistent rhonchi after initial treatment requiring continued nebulization 1
• High-risk comorbidities (pneumonia, cardiac arrhythmia, heart failure, diabetes, renal or liver failure) 1
• Inability to care for self at home 1

---

Discharge Planning

• Arrange pulmonary rehabilitation within 3 weeks after discharge to reduce readmissions and improve quality of life; initiating rehab during hospitalization increases mortality 1
• Optimize long-acting bronchodilator therapy (LAMA, LABA, or combinations) before discharge 1
• Do not step down from triple therapy (LAMA + LABA + ICS) during or immediately after an exacerbation, as inhaled corticosteroid withdrawal raises recurrent exacerbation risk 1
• Verify proper inhaler technique at discharge 1
• Provide smoking cessation counseling with nicotine replacement therapy and behavioral support for current smokers 1

---

Critical Pitfalls to Avoid

• Never use intravenous methylxanthines (theophylline/aminophylline) in acute exacerbations—they increase adverse effects without clinical benefit 1
• Never power nebulizers with oxygen in hypercapnic patients; use compressed air and provide supplemental oxygen via separate nasal cannula 1, 2
• Never delay NIV when criteria for acute hypercapnic respiratory failure are met (pH <7.35, PaCO₂ >45 mmHg persisting >30 minutes) 1
• Never administer high-flow oxygen without arterial blood-gas monitoring, as this worsens hypercapnic respiratory failure and increases mortality 1
• Never continue systemic corticosteroids beyond 5–7 days for a single exacerbation unless another indication exists 1